Amendments to the claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of claims:

1. (Currently amended): A[[~~n~~]] ~~compound selected from: a~~ compound of Formula (I) :



(I)

~~and~~ or a salt, solvate or physiologically functional derivative thereof, wherein:

R^1 ~~represents~~ is hydrogen, halogen or C_1-C_3alkyl;

R^2 ~~represents~~ is a 5 or 6-member aryl, heteroaryl, heterocyclic or alicyclic ring;

Z ~~represents~~ is $-(CH_2)_q-$ [[;]] , $-CH=CH-$ [[;]] , $-(CH_2)_pNHC(O)-$ [[;]] , $-(CH_2)_pNHC(O)NH-$ [[;]] , $-(CH_2)_pNHC(O)O-$ [[;]] , $-(CH_2)_pSO_2NR^3-$ [[;]] , $-(CH_2)_pNR^3SO_2-$ [[;]] , $-(CH_2)_nO-$ [[;]] , $-C(R^4R^5)O-$ or $-Y-W-X-$;

W ~~represents~~ is a 5 or 6-member aryl, heteroaryl, heterocyclic or alicyclic ring;

X and Y[[,]] ~~which may~~ are independently ~~be~~ present or absent, where present independently ~~represent~~ is $-(CH_2)_q-$ [[;]] , $-CH=CH-$ [[;]] , $-(CH_2)_pNHC(O)-$ [[;]] , $-(CH_2)_pNHC(O)O-$ [[;]] , $-(CH_2)_pNHC(O)NH-$ [[;]] , $-(CH_2)_pSO_2NR^3-$ [[;]] , $-(CH_2)_pNR^3SO_2-$ [[;]] , $-(CH_2)_pC(O)-$ [[;]] , $-(CH_2)_pNH-$ [[;]] , $-(CH_2)_pO-$ [[;]] , $-(CH_2)_pS-$ or $-(CH_2)_pO-CH_2-$;

n ~~represents an integer selected from~~ is 2, 3 ~~and~~ or 4;

p ~~represents an integer selected from~~ is 0, 1 ~~and~~ or 2;

q ~~represents an integer selected from~~ is 1, 2, 3 ~~and~~ or 4;

R^3 ~~represents~~ is hydrogen or methyl; and

R^4 and R^5 ~~, which may be the same or different,~~ are independently ~~represent~~ C_1-C_3alkyl; provided

(i) that when R^1 is hydrogen, Z is $-(CH_2)_n-$, and n is 2, then R^2 is other than para-chlorophenyl or para-methylphenyl; and

(ii) that a compound of Formula (I) is other than 2-(2-(((4-(phenyl)phenyl) amino)acetyl)amino)benzoic acid, 2-(2-(((4-phenyl)phenoxy)acetyl)amino) benzoic acid, 2-[[(4-cyclohexylphenoxy)acetyl]amino]benzoic acid, 2-[[3-[3-(4-chlorophenyl)-1,2,4-oxadiazol-5-yl]-1-oxopropyl]amino]benzoic acid or compound X



X.

2. (Original): A compound according to claim 1 wherein R^1 is hydrogen or methyl.

3. (Original): A compound according to claim 2 wherein R^1 is hydrogen.

4. (Currently amended): A compound according to claim 1 ~~any preceding claim~~ wherein R^2 is cyclohexyl, phenyl, pyridinyl, pyrimidinyl, pyridazinyl ~~and~~ or isoxazolyl.

5. (Currently amended): A compound according to claim 1 ~~any one of claims 1-3~~ wherein R^2 is selected from the group consisting of:





6. (Currently amended): A compound according to claim 1 ~~any one of claims 1-3~~ wherein R^2 is substituted phenyl.

7. (Currently Amended): A compound according to claim 6 wherein R^2 is phenyl substituted with one or two substituents ~~selected from~~ which are halogen C_{1-3}alkyl, C_{1-3}haloalkyl C_{1-3}alkoxy ~~and~~ or C_{1-3}haloakloxy.

8. (Currently amended): A compound according to claim 1 ~~any preceding claim~~ wherein Y is –O–, $-CH_2-$ or $-CH_2O-$.

9. (Currently amended): A compound according to claim 1 ~~any preceding claim~~ wherein X is absent or is $-SO_2NR^3-$, –NHC(O)– or –NHC(O)NH– .

10. (Currently amended): A compound according to claim 1 ~~any preceding claim~~ wherein Y is $-CH_2-$ and X is $-SO_2NR^3-$.

11. (Currently amended): A compound according to claim 1 ~~any one of claims 1-7~~ wherein Y is –O– and X is absent.

12. (Currently amended): A compound according to claim 1 ~~any preceding claim~~ wherein W is a 5 or 6 member aryl or heteroaryl ring.

13. (Original): A compound according to claim 12 wherein W is phenyl.

14. (Original): A compound according to claim 12 wherein W is a 5 member heteroaryl ring.

Claims 15-20 (Cancelled).

21. (Currently Amended): A method for the treatment of a human or animal subject having ~~disease~~ a condition characterised by under-activation of the HM74A receptor or in which activation of the receptor will be beneficial, which method comprises administering to said human or animal subject an effective amount of a compound ~~selected from: a compound~~ of Formula (Ia) :



(Ia)

~~And~~ or a salt, solvate or physiologically functional derivative thereof, wherein:

R^1 ~~represents~~ is hydrogen, halogen or C_1-C_3alkyl;

R^2 ~~represents~~ is a 5 or 6-member aryl, heteroaryl, or heterocyclic or alicyclic ring;

Z ~~represents~~ is $-(CH_2)_n-$ [[;]] , $-CH=CH-$ [[;]] , $-(CH_2)_pNHC(O)-$ [[;]] , $-(CH_2)_pNHC(O)NH-$ [[;]] , $-(CH_2)_pNHC(O)O-$ [[;]] , $-(CH_2)_pSO_2NR^3-$ [[;]] , $-(CH_2)_pNR^3SO_2-$ [[;]] , $-(CH_2)_qO-$ [[;]] , $-C(R^4R^5)O-$ or –Y-W-X– ;

W ~~represents~~ is a 5 or 6-member aryl, heteroaryl, heterocyclic or alicyclic ring;

X and Y[[,]] ~~which may~~ are independently ~~be~~ present or absent, where present independently ~~represent~~ is $-(CH_2)_q-$ [[;]] , $-CH=CH-$ [[;]] , $-(CH_2)_pNHC(O)-$ [[;]] , $-(CH_2)_pNHC(O)O-$ [[;]] , $-(CH_2)_pNHC(O)NH-$ [[;]] , $-(CH_2)_pSO_2NR^3-$ [[;]] , $-(CH_2)_pNR^3SO_2-$ [[;]] , $-(CH_2)_pC(O)-$ [[;]] , $-(CH_2)_pNH-$ [[;]] , $-(CH_2)_pO-$ or $-(CH_2)_pO\text{-}CH_2-$;

n ~~represents an integer selected from~~ is 2, 3 ~~and~~ or 4;

p ~~represents an integer selected from~~ is 0, 1 or 2;

q ~~represents an integer selected from~~ is 1, 2, 3 ~~and~~ or 4;

R^3 ~~represents~~ is hydrogen or methyl; and

R^4 and R^5 [[,]] ~~which may be the same or different,~~ are independently ~~represent~~ C_1-C_3alkyl.

22. (Currently Amended): A method according to claim 21 wherein the condition is a disorder of lipid metabolism ~~including dislipidaemia or hyperlipoproteinaemia~~ or an inflammatory disease ~~or condition~~.

23. (Currently amended): A pharmaceutical formulation comprising a compound according to claim 1 ~~any one of claims 1-14~~ in admixture with one or more physiologically acceptable diluents, excipients or carriers.

24. (Currently amended): A combination for administration together or separately, sequentially or simultaneously in separate or combined pharmaceutical formulations, said combination comprising a compound according to claim 1 ~~any one of claims 1-14~~ together with another therapeutically active agent.

25. (Currently amended): A pharmaceutical formulation comprising a compound according to claim 1 ~~any one of claims 1-14~~, plus a further active ingredient selected from the group consisting of statins, fibrates, bile-acid binding resins and nicotinic acid and one or more physiologically acceptable diluents, excipients or carriers.

26. (Currently Amended): A ~~method~~ process for the preparation of a compound of Formula (I):



(I)

in which R^1 ~~represents~~ is hydrogen, Z ~~represents~~ is -Y-W-X-, Y ~~represents~~ is $-(CH_2)_pO-$, p ~~represents the integer~~ is 1, and W, X and R^2 are as defined in claim 1, the ~~method~~ process comprising the steps of:

(i) amide bond formation by acetylation of an ester of anthranilic acid;

(ii) addition of W or W-X-R^2 by substitution of a leaving group;

(iii) deprotection of the anthranilic acid group;

and where desired or necessary converting a resultant free ~~acid or base~~ base or salt compound of Formula (I) into a physiologically acceptable salt ~~form~~ or free base ~~vice versa~~ or converting one salt ~~form~~ into another physiologically acceptable salt ~~form~~.

27. (Currently Amended): A ~~method~~ process according to claim 26 where in step (ii) comprises addition of W and a further step (ii)(a), addition of R^2, is included in the form of a further substitution reaction.

28. (Currently Amended): A ~~method~~ process for the preparation of a compound of Formula (I):



(I)

in which R^1, R^2 and Z are as defined in claim 1, the ~~method~~ process comprising the steps of:

(i) formation of an amide between the amine group of 2-amino-bezoic acid and an activated acyl transfer reagent derived from a carboxylic acid; and

(ii) where desired or necessary converting a resultant free base or acid ~~acid or base~~ compound of Formula (I) into a physiologically acceptable salt ~~form~~ or free base ~~vice versa~~ or converting one salt ~~form~~ into another physiologically acceptable salt ~~form~~.

29. (New): A method according to claim 22 wherein the disorder of lipid metabolism is dislipidaemia or hyperlipoproteinaemia.